Devereux, Richard B <br/><br/>
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.  [electronic resource] 

 -  Circulation  Sep 2004 
 - 1456-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/01.CIR.0000141573.44737.5A  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic beta-Antagonists--therapeutic use<br/>Aged<br/>Aged, 80 and over<br/>Angiotensin II Type 1 Receptor Blockers--therapeutic use<br/>Antihypertensive Agents--therapeutic use<br/>Atenolol--therapeutic use<br/>Blood Pressure--drug effects<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Heart Rate--drug effects<br/>Heart Ventricles--diagnostic imaging<br/>Humans<br/>Hypertension--complications<br/>Hypertrophy, Left Ventricular--diagnostic imaging<br/>Losartan--therapeutic use<br/>Male<br/>Middle Aged<br/>Organ Size<br/>Prospective Studies<br/>Treatment Outcome<br/>Ultrasonography